Andrin Oswald

Novartis: FDA granted accelerated approval of Bexsero® for active immunization to prevent invasive meningococcal disease caused by meningitis B

With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have…

9 years ago

Vaccination: Novartis to provide meningococcal serogroup B (MenB) vaccine Bexsero® to University of California Santa Barbara

FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is…

10 years ago

Novartis vaccination program with MenB vaccine Bexsero® began at Princeton University following campus outbreak

Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials Bexsero, already…

10 years ago